Lung cancer is by far the most lethal form of cancer in the U.S., accounting for about 1 in 5 of all cancer deaths.
Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...
13h
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature ...
A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...
An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...
On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...
New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...
In a new study that challenges long-held views on lung cancer, University of Kentucky Markey Cancer Center researchers have ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
The following is a summary of "Mediastinal staging lymph node probability map in non-small cell lung cancer,” published in the March 2025 issue of Respiratory Research by Bordas-Martinez et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback